文献速递腹部MR

化疗后新发良性局灶性肝脏病灶的MRI表现:早期与晚期随访中的不同特征

MRI findings of newly present benign focal hepatic observations following chemotherapy: distinct features in early- and late-term follow-up.
PubMed 文献 · Eur Radiol · 2024-11-12

本回顾性单中心病例对照研究纳入43例化疗后新发良性局灶性肝脏病灶的癌症患者(93个病灶),评估钆塞酸二钠增强MRI特征并与34例93个肝转移瘤对照。早期随访出现的病灶多边界不清、DWI阴性、HBP斑片状低信号、血管穿行无扭曲,91.9%在4-20个月内消退;晚期随访病灶呈FNH样,56.3%见HBP环状强化,66.7%患者随访中病灶增大和/或增多。

要点

  • 化疗后早期(中位3个月)新发良性病灶多DWI阴性、HBP斑片状低信号、血管穿行无扭曲,多数可自行消退。
  • 化疗后晚期(中位34个月)新发FNH样病灶可表现为HBP环状强化,随访中可增大或增多。
  • 结合Gd-EOB-DTPA-MRI特征及时间变化,有助于将化疗相关良性病灶与肝转移瘤鉴别。

核心结论

  • 化疗后早期与晚期随访中新发的良性局灶性肝脏病灶在Gd-EOB-DTPA-MRI上具有不同影像特征,早期病灶倾向于自行消退,而FNH样病灶可在随访中增大和增多。

研究设计与样本

  • 回顾性单中心病例对照研究,纳入2010年1月至2020年12月间43例化疗后新发良性局灶性肝脏病灶的癌症患者(93个病灶),并与34例93个肝转移瘤对照;采用钆塞酸二钠增强MRI评估病灶出现时间、影像特征及随访变化。

关键影像表现/征象

  • 早期随访出现的病灶(22例45个,化疗后中位3个月,范围1-6个月)中,64.4%在HBP图像上边界不清,84.4%DWI阴性,88.9%HBP呈斑片状低信号,80.0%见血管穿行无扭曲。
  • 晚期随访出现的病灶(21例48个,化疗后中位34个月,范围12-60个月)按MRI特征诊断为FNH样病灶,56.3%见HBP环状强化,66.7%患者随访中病灶增大和/或增多。
  • 早期随访病灶中91.9%在4-20个月内消退。

诊断标准与关键数值

  • 早期随访病灶(化疗后中位3个月,范围1-6个月):HBP边界不清64.4%,DWI阴性84.4%,HBP斑片状低信号88.9%,血管穿行无扭曲80.0%,91.9%在4-20个月内消退。
  • 晚期随访病灶(化疗后中位34个月,范围12-60个月):按MRI特征诊断为FNH样病灶,HBP环状强化56.3%,66.7%患者随访中病灶增大和/或增多。

临床应用与阅片要点

  • 化疗后早期新发良性病灶多表现为DWI阴性、HBP斑片状低信号且血管穿行无扭曲,随访中多数可消退,作者指出结合Gd-EOB-DTPA-MRI表现及其时间变化可与转移瘤鉴别,加深对其认识可避免不必要的活检或手术切除。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVE: To evaluate gadoxetic acid-enhanced (Gd-EOB-DTPA) MRI features of newly detected benign focal hepatic observations after chemotherapy.

METHODS: In this retrospective single-center case-control study, we enrolled a cohort of 43 cancer patients with 93 newly detected benign focal hepatic observations after chemotherapy between January 2010 and December 2020. We evaluated several parameters including the delay of occurrence after chemotherapy, imaging features, and imaging follow-up. These parameters were compared with those observed in a control group comprising 34 patients with 93 hepatic metastases.

RESULTS: For focal hepatic observations occurring at early-term follow-up (delay of occurrence after chemotherapy, median 3 months, range 1-6 months) with 22 patients encompassing 45 lesions, most lesions exhibited an ill-defined margin on HBP images (64.4%), negative on diffusion-weighted images (84.4%), mottled hypo-intensity on hepatobiliary phase images (88.9%), and undistorted vessels traversing the lesions (80.0%). Follow-up imaging indicated that 91.9% of these lesions resolved within 4-20 months. For focal hepatic observations occurring at late-term follow-up (delay of occurrence after chemotherapy, median 34 months, range 12-60 months) with 21 patients encompassing 48 lesions, which were diagnosed as focal nodular hyperplasia (FNH)-like lesions based on MRI features. A hepatobiliary ring enhancement was observed in 56.3% of lesions, and 66.7% of patients showed an increase in lesion size and/or number during follow-up imaging.

CONCLUSION: Focal hepatic observations occurring at early-term and late-term follow-ups after chemotherapy have distinctive imaging features at Gd-EOB-DTPA-MRI. Early-term focal observations tend to resolve spontaneously, whereas FNH-like lesions can increase in size and number during follow-up.

KEY POINTS: Question Focal benign liver lesions related to chemotherapy-induced hepatic injury were reported in recent years, often leading to confusion with metastasis and resulting in misdiagnosis. Findings Chemotherapy-induced focal hepatic observations identified during early- and late-term follow-up exhibit distinct imaging characteristics on Gd-EOB-DTPA-MRI and demonstrate varying temporal changes. Clinical relevance Chemotherapy-induced hepatic observations can be differentiated from metastasis based on Gd-EOB-DTPA MRI findings and their temporal changes. A deeper understanding of their findings can avoid unnecessary biopsies or surgical resections.

来源:Eur Radiol,查看原文。版权归原作者所有。

引用

  1. Wang Y, Mao S, Huang R, et al. MRI findings of newly present benign focal hepatic observations following chemotherapy: distinct features in early- and late-term follow-up. Eur Radiol. 2024. PMID: 39532721. doi:10.1007/s00330-024-11185-6

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。